Vertex Pharmaceuticals' unchanged guidance and disappointing trial outcomes for its investigative pain relief treatment led ...

Vertex Pharmaceuticals ( VRTX) plunged after Q2 earnings and is now down 21% over the past year. The company has historically ...

Vertex Pharmaceuticals Incorporated's stock drop is overblown. With strong CF revenue, pipeline potential, & insider ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published 10 Big Names Bleed Double Digits. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) is one of the ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $460.0 for Vertex Pharmaceuticals, spanning the last ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $481.56, ...

Vertex Pharmaceuticals shows promising signs despite a recent price drop. Strong fundamentals underscore its market position, ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

A joint venture led by locally based REIT Diversified Healthcare Trust (NASDAQ: DHC) has received $1 billion for the refinancing of the Vertex Pharmaceuticals headquarters facility in Boston. A ...